Digestive Diseases and Sciences最新文献_第10页

Clinical Evaluation of Patients with Elevated Serum Lipase. 血清脂肪酶升高患者的临床评价。

IF 2.5 4区医学

Digestive Diseases and Sciences Pub Date : 2025-03-21 DOI: 10.1007/s10620-025-08929-9

Arjun Chatterjee, Renan Prado, Hassan Siddiki, Tyler Stevens

引用次数: 0

Transanal Opening of the Intersphincteric Space (TROPIS) Is Effective in Managing High Complex as It Is Based on Garg Cardinal Principles. 经肛门括约肌间隙开孔（TROPIS）是一种基于Garg基本原理的治疗高复杂性的有效方法。

IF 2.5 4区医学

Digestive Diseases and Sciences Pub Date : 2025-03-20 DOI: 10.1007/s10620-025-08980-6

Pankaj Garg, Nicola Clemente, James C W Khaw

引用次数: 0

Hepatitis B Risk in Vaccinated Patients with Celiac Disease - Do Titers Matter? 接种疫苗的乳糜泻患者乙型肝炎风险-滴度重要吗？

IF 2.5 4区医学

Digestive Diseases and Sciences Pub Date : 2025-03-20 DOI: 10.1007/s10620-025-08998-w

Nawras Habash, Imad Absah

引用次数: 0

Does Short Myotomy Really Not Reduce the Risk of Reflux Esophagitis and Pathologic Acid Exposure After Peroral Endoscopic Myotomy? 短切肌真的不能降低经口内窥镜切肌后反流性食管炎和病理性酸暴露的风险吗？

IF 2.5 4区医学

Digestive Diseases and Sciences Pub Date : 2025-03-20 DOI: 10.1007/s10620-025-08995-z

Jiali Wang, Han Zhang

引用次数: 0

Insights on Advanced Age as a Predictor of TIPS Outcomes in Elderly Patients. 高龄作为老年患者TIPS预后预测因子的见解

IF 2.5 4区医学

Digestive Diseases and Sciences Pub Date : 2025-03-20 DOI: 10.1007/s10620-025-08991-3

Rusong Li, Chengfei Du

引用次数: 0

Older Adults with Inflammatory Bowel Disease Epidemiology in the United States: 2000-2021. 美国老年炎症性肠病流行病学：2000-2021

IF 2.5 4区医学

Digestive Diseases and Sciences Pub Date : 2025-03-19 DOI: 10.1007/s10620-025-08976-2

Pojsakorn Danpanichkul, Yanfang Pang, Chawinthorn Vuthithammee, Disatorn Dejvajara, Priyata Dutta, Passisd Laoveeravat, Omar Al Ta'ani, Agnes Hy Ho, Chun Wei Pan, Nicole Shu Ying Tang, Kanokphong Suparan, Rashid N Lui, Donghee Kim, Siew C Ng, Gursimran Singh Kochhar, Francis A Farraye, Karn Wijarnpreecha

{"title":"Older Adults with Inflammatory Bowel Disease Epidemiology in the United States: 2000-2021.","authors":"Pojsakorn Danpanichkul, Yanfang Pang, Chawinthorn Vuthithammee, Disatorn Dejvajara, Priyata Dutta, Passisd Laoveeravat, Omar Al Ta'ani, Agnes Hy Ho, Chun Wei Pan, Nicole Shu Ying Tang, Kanokphong Suparan, Rashid N Lui, Donghee Kim, Siew C Ng, Gursimran Singh Kochhar, Francis A Farraye, Karn Wijarnpreecha","doi":"10.1007/s10620-025-08976-2","DOIUrl":"https://doi.org/10.1007/s10620-025-08976-2","url":null,"abstract":"Background: As the United States population ages, the incidence and prevalence of inflammatory bowel disease (IBD) among older adults are on the rise.Aims: This study provides updated estimates of the IBD burden in older adults and examines changes from 2000 to 2021.Methods: We analyzed data on IBD incidence, prevalence, and disability-adjusted life years (DALYs) in older adults (> 70 years) in the United States from the Global Burden of Disease Study 2021, stratified by sex and state. Using the Joinpoint regression model, we evaluated age-standardized rate changes from 2000 to 2021.Results: The study estimated 11,250 new cases, 180,880 prevalent cases, and 80,410 DALYs from IBD in older adults in the United States in 2021. In 2021, older adults-onset represented 15% of the total IBD population in the United States, a 3% increase since 2000. Between 2000 and 2021, the incidence (Annual percent change [APC]: 0.58%, 95%CI 0.50 to 0.66%) and DALYs rates (APC: 0.34%, 95%CI 0.07 to 0.62%) increased, while the prevalence rates remained stable. Incidence rate increased at a higher extent in older adults-onset IBD in females compared to that of males. Forty-seven states experienced increased older adults-onset IBD incidence rates during this period.Conclusion: From 2000 to 2021, the incidence and disability rates of older adults-onset IBD increased in the United States. Although older males initially had higher incidence rates, the rates have disproportionately increased among older females. The proportion of older adults-onset IBD cases and related disability has also grown, highlighting the urgent need for strategies to address the rising IBD burden in older adults.","PeriodicalId":11378,"journal":{"name":"Digestive Diseases and Sciences","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143662756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Rare Cause of Small Bowel Obstruction with "Targets, Combs and Rash": Isolated Lupus Enteritis with Erythema Annulare Centrifugum. 一个罕见的小肠梗阻的“目标，梳状和皮疹”的原因：孤立性狼疮性肠炎与离心环形红斑。

IF 2.5 4区医学

Digestive Diseases and Sciences Pub Date : 2025-03-19 DOI: 10.1007/s10620-025-08981-5

Jahnvi Dhar, Pankaj Gupta, Saroj Kant Sinha, Jayanta Samanta

引用次数: 0

A Survey on Endoscopy-Related Musculoskeletal Injuries in Japanese Endoscopists Focused on Injury Sites and Risk Factors. 日本内窥镜相关肌肉骨骼损伤调查：损伤部位和危险因素

IF 2.5 4区医学

Digestive Diseases and Sciences Pub Date : 2025-03-19 DOI: 10.1007/s10620-025-08953-9

Shoko Ono, Sae Nakajima, Sae Owada, Natsumi Tomita, Momoko Tsuda, Michiko Yamada, Shinichi Katsuki, Naoya Sakamoto

{"title":"A Survey on Endoscopy-Related Musculoskeletal Injuries in Japanese Endoscopists Focused on Injury Sites and Risk Factors.","authors":"Shoko Ono, Sae Nakajima, Sae Owada, Natsumi Tomita, Momoko Tsuda, Michiko Yamada, Shinichi Katsuki, Naoya Sakamoto","doi":"10.1007/s10620-025-08953-9","DOIUrl":"https://doi.org/10.1007/s10620-025-08953-9","url":null,"abstract":"Purpose: Endoscopy examinations require complex and repetitive maneuvers that can put a strain on the musculoskeletal system, and there have been recent reports on endoscopy-related injuries (ERI). A survey was carried out with a focus on sites of injuries and risk factors for Japanese endoscopists.Methods: A 29-item web survey including non-identifiable demographic data, practice information, ERI, usability of endoscopes and ergonomics practice was carried out for Japanese endoscopists. ERI were defined as past or present endoscopy-related muscle and joint disorders including pain, discomfort, movement restriction, and numbness.Results: Data for 352 endoscopists were analyzed after excluding 49 endoscopists who had injuries not related to endoscopy. The incidences of ERI were 55.6% (150/270) in males and 61.0% (50/82) in females (not significant). The age of the endoscopists (≥ 36 years) and total number of endoscopy procedures per week (≥ 28) were found to be significant factors associated with ERI. Risk factors for hand injuries were total number of endoscopy procedures per week (≥ 28) and glove size (≥ size 7) for males and age (≥ 36 years) for females. The height (≥ 172 cm) was associated with neck injuries in male endoscopists. Also, number of ERCP procedures per week (≥ 1) in males and age (≥ 36 years) in females were risks for lower back injuries.Conclusion: ERI occurred at a high rate among Japanese endoscopists by a self-reporting survey. It is necessary to clarify the relationships between the site of injury and risk factors and take preventive measures.","PeriodicalId":11378,"journal":{"name":"Digestive Diseases and Sciences","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Persistence and Efficacy of Ustekinumab in Crohn's Disease After Anti-TNF Failure: An Observational Study. 抗肿瘤坏死因子失效后Ustekinumab治疗克罗恩病的持久性和疗效：一项观察性研究

IF 2.5 4区医学

Digestive Diseases and Sciences Pub Date : 2025-03-19 DOI: 10.1007/s10620-025-08978-0

I Latras-Cortés, J C Sáez Hortelano, P Suárez-Álvarez, N Cano-Sanz, L Ortega-Valin, M Sierra-Ausín

{"title":"Persistence and Efficacy of Ustekinumab in Crohn's Disease After Anti-TNF Failure: An Observational Study.","authors":"I Latras-Cortés, J C Sáez Hortelano, P Suárez-Álvarez, N Cano-Sanz, L Ortega-Valin, M Sierra-Ausín","doi":"10.1007/s10620-025-08978-0","DOIUrl":"https://doi.org/10.1007/s10620-025-08978-0","url":null,"abstract":"Background: Anti-TNF treatment failure in Crohn's disease is common, and the literature on the selection of subsequent treatment is scant. Ustekinumab may be associated with high persistence rates and it appears to be effective in perianal disease.Aims: Primary objective: persistence, clinical, and biologic remission with ustekinumab.Secondary objectives: Persistence of the first biologic therapy, reasons for change of treatment, need for dose optimization, surgery, hospitalizations, and adverse events with ustekinumab.Methods: Retrospective, observational, single-center study from a prospective database of Crohn's disease adult patients receiving ustekinumab after failure of anti-TNF or vedolizumab. A sub-analysis was performed to evaluate ustekinumab persistence after the approval of risankizumab and upadacitinib.Results: Mean duration with ustekinumab was 27.65 months (SD 18.27) and persistence was 86.76%. Clinical remission was 40.63% at week 4, 54.35% at week 8, 54.9% at year 1, 76.92% at year 4, and 100% at year 5. Persistence with ustekinumab was longer than with anti-TNF: year 1, 93.2 vs 72.06%; year 2, 89.4 vs 45.59%; and year 3, 86.1 vs 30.88%. Just over one-third (36.76%) of patients required dose optimization. Nine (13.24%) patients stopped treatment due to primary non-response [1 (1.47%)], loss of response [5(7.35%)], and adverse events [3 (4.41%)]. Eleven (16.18%) patients needed surgery and hospitalization. After the approval of upadacitinib and risankizumab, ustekinumab persistence was 80.88%. Seven (70%) of the patients with perianal disease achieved clinical remission and 4 (40%) completed fistula healing.Conclusions: Ustekinumab may have better persistence as a second-line treatment compared to anti-TNF and may be effective in perianal disease.","PeriodicalId":11378,"journal":{"name":"Digestive Diseases and Sciences","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143662759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of Antihypertensive and Lipid-Lowering Agents on Hepatocellular Carcinoma Risk in Patients with Fatty Liver Disease and Diabetes. 降压药和降脂药对脂肪肝和糖尿病患者肝癌风险的影响

IF 2.5 4区医学

Digestive Diseases and Sciences Pub Date : 2025-03-19 DOI: 10.1007/s10620-025-08935-x

Hyo Jung Cho, Eunyoung Lee, Soon Sun Kim, Jae Youn Cheong

{"title":"Impact of Antihypertensive and Lipid-Lowering Agents on Hepatocellular Carcinoma Risk in Patients with Fatty Liver Disease and Diabetes.","authors":"Hyo Jung Cho, Eunyoung Lee, Soon Sun Kim, Jae Youn Cheong","doi":"10.1007/s10620-025-08935-x","DOIUrl":"https://doi.org/10.1007/s10620-025-08935-x","url":null,"abstract":"Background/aim: This study aimed to evaluate the effects of antihypertensives, lipid-lowering agents, and antiplatelet medications on hepatocellular carcinoma (HCC) risk in patients with fatty liver disease (FLD) and type 2 diabetes (T2D).Method: Using data from Korea Health Insurance Review and Assessment Service, 212,443 FLD-T2D patients were analyzed through Cox regression, propensity score matching (PSM), and Kaplan-Meier analysis. The analysis considered medication use and its relation to HCC development. Cohort admission day was set as the date of the first oral hypoglycemic prescription.Results: The multivariate Cox regression analysis revealed that old age, male sex, chronic viral hepatitis, alcoholic liver disease, liver cirrhosis, using a combination of insulin and oral hypoglycemic agents for antidiabetic treatment, and calcium channel blocker (CCB) use were significantly correlated with higher HCC development risk, whereas dyslipidemia and statin, ezetimibe, and fibrate use was correlated with lower HCC risk, in the study cohort of 212,443 patients. Patients who used statins (hazard ratio [HR] = 0.58, 95% confidence interval [CI] = 0.42-0.80, P = 0.001) and fibrates (HR = 0.46, 95% CI = 0.22-0.93, P = 0.031) showed a significantly lower risk of HCC development even after PSM. In contrast, CCB use was linked to an elevated HCC risk (HR = 1.35, 95% CI = 1.05-1.72, P = 0.019), highlighting the differential impact of various medications on HCC incidence.Conclusion: The use of specific medications, such as statins and fibrates, may offer protective effects against HCC in patients with FLD-T2D, whereas that of CCB may increase the risk. This underscores the importance of tailored medication strategies for the management of chronic conditions.","PeriodicalId":11378,"journal":{"name":"Digestive Diseases and Sciences","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143662804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0